Predictive Models for Arteriovenous Fistula Maturation

Julien Al Shakarchi¹
Damian McGrogan¹
Sabine Van der Veer²
Matthew Sperrin²
Nicholas Inston¹

¹ Department of Renal Surgery, University Hospital Birmingham, UK.
² University of Manchester, UK

Correspondence address:
Julien Al Shakarchi
Department of Renal Surgery
University Hospital Birmingham
Birmingham, UK
j.alshakarchi@nhs.net

Keywords: Arteriovenous fistula, haemodialysis, Model, Maturation, Patency
ABSTRACT

Haemodialysis (HD) is a lifeline therapy for patients with end stage renal disease (ESRD). A critical factor in the survival of renal dialysis patients is the surgical creation of vascular access and international guidelines recommend arteriovenous fistulas (AVF) as the gold standard of vascular access for haemodialysis. Despite this, AVFs have been associated with high failure rates. Although risk factors for AVF failure have been identified, their utility for predicting AVF failure through predictive models remains unclear. The objectives of this review are to systematically and critically assess the methodology and reporting of studies developing prognostic predictive models for AVF outcomes and assess them for suitability in clinical practice.

Electronic databases were searched for studies reporting prognostic predictive models for AVF outcomes. Dual review was conducted to identify studies that reported on the development or validation of a model constructed to predict AVF outcome following creation. Data was extracted on study characteristics, risk predictors, statistical methodology, type of model as well as validation process. We included 4 different studies reporting five different predictive models. Parameters identified that were common to all scoring system were age and cardiovascular disease.

This review has found a small number of predictive models in vascular access. The disparity between each study limits the development of a unified predictive model.

INTRODUCTION
Predictive models, both diagnostic and prognostic, are tools that combine multiple predictors to obtain a risk or probability. They are becoming increasingly described in the medical literature and used in clinical practice. These models have considerable potential to contribute to the decision-making process regarding the management of a patient. Typically, they combine several clinical, investigational or patient related measures to calculate the likelihood of an outcome.

Haemodialysis (HD) is a life preserving therapy for patients with end stage renal disease (ESRD). It is estimated that over 1.5 million patients receive regular HD treatment worldwide with the number growing at a rate of around 7% (1). A critical factor in the survival of renal dialysis patients is the surgical creation of vascular access and international guidelines recommend arteriovenous fistulas (AVF) as the gold standard of vascular access for HD.(2,3) Unfortunately, AVFs have been associated with high failure rates, being reported at 30 to 50% predominately due to aggressive pathological process termed venous intimal hyperplasia (VIH).(4,5) Numerous factors have been described as having an effect on the success rate and therefore a prognostic predictive model would be extremely important in planning in clinical practice for example guiding decisions on the site of the AVF.(6) Existing reviews of prediction models in other diseases have shown that model design is critical and many models are poorly developed with weaknesses in their methodology, validation and reporting.(7)

The objectives of our review are to systematically and critically assess the methodology and reporting of studies developing prognostic predictive models for AVF outcomes and assess them for suitability in clinical practice.

METHOD
Searches of Pubmed central, Ovid Medline and Ovid Embase were performed using the combination of the following search terms: haemodialysis, haemofiltration or renal failure with vascular access, arteriovenous fistula or arteriovenous shunt in addition to the Haynes tool for finding prognostic prediction models to identify suitable published articles. In addition, the references cited in selected articles were reviewed for any further relevant available studies as well as our personal reference list. Articles were not restricted to any language and searches were carried out up to 31st May 2015. Grey literature was not searched or included. The systematic review was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.(8) Articles were included if they aimed to develop a multivariable prognostic predictive model for AVF maturation or patency outcomes. Articles were excluded if they did not develop a new model or the outcome was different from the inclusion criteria. Two reviewers (J.A. and D.M.) independently identified articles and screened them for inclusion. Disagreements were solved by consensus between authors. Where this was not possible, a 3rd opinion (N.I) was sought. Eligible articles were used to develop a potential prognostic assessment tool for predicting patency of arteriovenous fistula at 1-year. Studies that assess causal effect of a predictor(s) without modelling were excluded. From each study, we extracted data on study design, population, outcome definition, setting, demographics, the number of patients included, the number of variables tested as predictors, model development and evaluation, the type of statistical model, using a data extraction sheet. Each study underwent assessment using the TRIPOD statement.(9)

RESULTS
A total of 1378 articles and abstracts were identified using our search strategy. After screening the contents of the abstract, 16 full text articles underwent assessment for eligibility and quality inspection of methodology. (Figure 1) Following the assessment, 4 articles were found to be eligible for the review. (Table 1) One paper proposed two different models and therefore a total of five models have been included in our study. Three models were developed using North American data from Canada (10) and United States (11) and the other two models were European from the United Kingdom (12,13). Of note, the two British papers only focused on one type of AVF each (radiocephalic & snuff box).(12,13)

Figure 1 Flowsheet of results of search strategy with inclusion and exclusions following searches and screening.
The number of participants included in the development of the prediction models was clearly reported in all four studies, ranging from 218 to 422 patients. The prognostic predictive models included a median of five risk predictors. The most commonly identified risk predictors included age, venous diameter and CVD. Three models used multivariable regression model whilst the other two models used a series of separate univariable cox regression analyses. All studies clearly identified the type of statistical method that they used to derive the prediction model, two were derived using a Cox proportional hazards model (12,13) and three models used logistic regression (10,11).

All five studies claimed to have carried out some form of evaluation of the prediction model. Three models (10,11) (60%) conducted an internal validation of the prediction model with bootstrapping, with one of them also using an internal cross validation and external validation (11), In our opinion two studies did not sufficiently assess their models to validate them.(12,13)

Three studies (11,12,13) (60%) derived simplified scoring systems from the risk prediction models. One study (11) derived a simple points system by rounding odds ratios to the nearest integer, whereby the resulting score would be a simple summation of the integers. One study (12) derived a simple scoring system by giving an integer of 1 for all significant variables however they did not actually use the hazard ratios from the cox model. The second study (13) used a similar simple method, however decided to give two significant variables an integer of 2 due to their higher hazards ratio. Parameters identified that were common to all scoring system were age and CVD (cardiovascular disease). Recent studies have confirmed both age and CVD as a risk factor in VA outcomes which supports both as potential prognostic markers.(14)

Previous access was identified as a risk factor in two studies and specifically contralateral previous access. Venous diameter, a major factor in access planning was
only noted in three models although studies assessing outcome using vein size less than a pre-defined threshold (e.g. <2mm cephalic vein at wrist) show a strong correlation with failure.(6)

Dialysis dependency and BP was noted in two studies. Whilst studies subdividing patients into pre-dialysis and post dialysis AVF formation show better outcomes for the former this may be confounded by multiple factors such as previous access attempts, central venous catheters, uraemia and overall clinical co-morbidity.(6)

In access naïve patients AVF outcome was no different than in patients who had already started dialysis although in patients where access was created on the ipsilateral side as a previous CVC had worse outcomes. This is consistent with previous access being a parameter.

Ethnicity which has previously shown to affect outcome was only used in one study may reflect the low level of ethnic diversity in the studies rather than a true reflection of ethnicity as a risk.(11)

Pre-existing disease such as diabetes was only a risk in one model although other markers of arterial disease (previous cerebrovascular accident /previous lower limb angioplasty/peripheral vascular disease) were used. The contribution of arterial factors to AVF outcome is poorly defined and more accurate measures may be required to enable inclusion in prognostic models.

One model used absent intra-operative thrill as a strong, but not unexpected marker of negative outcome.

**DISCUSSION**

Haemodialysis is a lifeline for end stage renal failure patients with vascular access
being a major component of survival. Arteriovenous fistulas have been described as the gold standard due to its potential long-term patency, decreased rate of complications such as infection and overall survival benefit. (15) Despite this a major limitation of AVFs is the need for the vein to mature to a size large enough to be needled for haemodialysis. A number of factors have been associated with failure of maturation and this has been described widely in the current literature. (6) These include both patient and surgical variables.

In the general medical literature, scoring systems and predictive models have been widely recognized as useful tools in stratifying patients and predicting outcomes in cohorts of patients. In vascular access, the ability to predict successful maturation, or high risk of failure to mature may allow tailoring of clinical practice to individual patients and allow better planning of procedure and improved success. In common with many areas of vascular access where the current literature has little evidence there is a lack of available data on predictive models and this review could only find four eligible studies with a total of five models being described. This is a limitation to this review, although it does highlight a key area for future research. Only one paper was found to attempt to validate the available models, it would suggest that these are not widely used in clinical practice. (16) The lack of demonstration of validation and performance evaluation of these models on new populations makes it impossible to recommend these models. Further testing and validation by a different group of investigators in different patient cohorts is necessary. More advanced statistical approaches such as boot strapping to internally validate the predictive model may be used.

A weakness of comparing these models is the heterogeneity of outcomes that were used in the available models in particular AVF maturation, AVF non-maturation or AVF patency. (10,11,12,13) This is a typical problem in studies of vascular access as
different and often non-standardized outcomes are commonly described in different studies making comparison challenging and recommendations for standard outcome measures is mandated.(17)

The number of patients involved in the modelling process in the identified studies (n=218 to 422) compares poorly to available models on other topics such as end stage renal failure where numerous models used over 5000 patients.(7) Compared to models used in other topics, those available to this review use few variables. The results of haemodialysis fistula maturation study (18) will hopefully yield more data for predictive modelling with a higher number of patients and potentially more predictive variables.

In conclusion this review has found a small number of predictive models in vascular access. The disparity between each study limits the development of a unified predictive model and therefore we recommend more research is required in this field. The utility of an accurate well-designed predictive model, which could be applicable to a clinical setting, would provide benefit in the planning and tailoring of vascular access for haemodialysis.

Conflicts of interest
None declared

Acknowledgements
SV is a fellow of the methods support team of European Renal Best Practice, supported by a grant of the European Renal Association- European Dialysis Transplantation Association.
References


7. Collins GS, Omar O, Shanyinde M, Yu LM. A systematic review finds prediction models for chronic kidney disease were poorly reported and often developed using inappropriate methods. *J Clin Epidemiol*. 2013 66:268-277


9. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD):


12. Twine CP, Haidermota M, Woolgar JD, Gibbons CP, Davies CG. A Scoring System (DISTAL) for Predicting Failure of Snuffbox Arteriovenous Fistulas. *Eur J Vasc Endovasc Surg* 2012 44:88-91


### Tables

#### Table 1

<table>
<thead>
<tr>
<th>TRIPOD statement checklist</th>
<th>Feldman(^{16})</th>
<th>Lok(^{11})</th>
<th>Twine(^{12})</th>
<th>Bosanquet(^{13})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Abstract</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Background</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Source of data</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Participants</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Outcome</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Predictors</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Sample size</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Missing data</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Statistical analysis</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Risk groups</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development/validation</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model development</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Model specification</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Model performance</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model updating</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Limitations</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interpretation</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Implications</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Supplementary information</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funding</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Study</td>
<td>Year of publication</td>
<td>Country</td>
<td>Design</td>
<td>Study population</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------------------</td>
<td>---------</td>
<td>---------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Feldman (10)</td>
<td>2003</td>
<td>US</td>
<td>Prospective cohort study</td>
<td>ESRF patients &gt;18</td>
</tr>
<tr>
<td>Feldman (10)</td>
<td>2003</td>
<td>US</td>
<td>Prospective cohort study</td>
<td>ESRF patients &gt;18</td>
</tr>
<tr>
<td>Lok (11)</td>
<td>2006</td>
<td>Canada</td>
<td>Prospective cohort study</td>
<td>ESRF patients &gt;18</td>
</tr>
<tr>
<td>Twine (12)</td>
<td>2012</td>
<td>UK</td>
<td>Retrospective cohort study</td>
<td>ESRF Patients &gt;18 Snuffbox fistulas</td>
</tr>
<tr>
<td>Bosanquet (13)</td>
<td>2015</td>
<td>UK</td>
<td>Retrospective cohort study</td>
<td>ESRF Patients &gt;18 Forearm fistulae</td>
</tr>
</tbody>
</table>